Introduction: Ocular toxoplasmosis, caused by the protozoan Toxoplasma gondii, often presents as an inflammatory lesion involving the choroid and retina. In many countries, it represents the most common cause of posterior uveitis. One of the typical forms is recurrent, unilateral, necrotizing retinitis with secondary choroiditis adjacent to a pigmented retinochoroidal scar, with or without involvement of the vitreous body. Standard treatment involves oral administration of pyrimethamine and sulfadiazine in combination with glucocorticosteroids. Other agents that may be used in treatment include azithromycin, trimethoprim–sulfamethoxazole, clindamycin, and atovaquone. However, the considerable toxicity of these drugs and their systemic combinations necessitates the search for alternative therapeutic approaches. One such option is local treatment in the form of intravitreal injections in cases of ocular reactivation of infection. Material, methods, and results: The present report outlines an effective diagnostic and therapeutic process in a 28-year-old patient in the second trimester of pregnancy with reactivation of a Toxoplasma gondii–related scar located along the papillomacular bundle, with partial involvement of the macula. Conclusions: Intravitreal injection of 1 mg of clindamycin and 400 µg of dexamethasone is an acceptable and safe alternative to standard treatment. This approach is associated with greater patient convenience and a safer systemic adverse-effect profile. The treatment is effective and, in certain patient groups – including pregnant women – may be the only viable option.